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Diabetes is a major global health problem. In Finland like elsewhere its prevalence has increased rapidly. 
While diabetes is a strong risk factor for complications including micro- and macrovascular diseases, it is 
also associated with several comorbidities. Although the outcomes of diabetes care have improved, the 
increasing prevalence of diabetes will request additional resources in health care. For planning measures to 
tackle challenges resulted from diabetes and to evaluate diabetes care efficient tools for monitoring are 
needed. This publication describes the structure of the diabetes database compiled in the Diabetes in Fin-
land (FinDM) project to monitor diabetes and its care. The publication presents the methods used to con-
struct the database and to define the main indicators used as well as reviews research carried out using the 
earlier editions on the FinDM data.  
The FinDM project aims to explore the incidence, prevalence, and related complications and comorbidities 
as well as care and cost of care of diabetes in Finland. The purpose is to form a comprehensive description 
of diabetes and its consequences and to comprise all persons with diabetes in Finland. Further, the aim is to 
extend the database to cover data related to effectiveness and quality of care and use of resources in prima-
ry and specialised health care.  
In compiling the FinDM database, several national administrative registers were used to identify potential 
persons with diabetes diagnosis between 1964 and 2017. Comprehensive follow-up data were collected 
from various register sources. Inclusion and exclusion criteria were defined for the data and alcoritms 
drawing on register data were developed to identify different types of diabetes, comorbidities and compli-
cations.  
The current FinDM database comprises data on 1,151,199 distinct individuals, of whom 887,210 were de-
fined as persons with diabetes. The FinDM database has reached a good coverage by 2017 with compre-
hensive follow-up data. In the future, linkage of the database to the primary health care and diagnostic data 
is needed. Further, a faster updating of data is a necessity to ensure up-to-date information. Thus far, some 
60 research publications have been published on a wide scope concerning diabetes and its complications. 
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Background 
Diabetes is a major health problem in Finland and globally. In 2002 the number of people in Finland with 
diagnosed diabetes was under 200 000 (Niemi and Winell 2005). In a Finnish study over 10 000 people in 
Finland were tested in 2007 with oral glucose tolerance test. It showed that two thirds of persons with type 
2 diabetes (T2D) did not know they had the disease (Salopuro et al 2010). It was also estimated that the 
number of persons with T2D had doubled every seven years until the year 2000 (Niemi and Winell 2005).  
Globally, the number of people living with diabetes is estimated to be 463 million corresponding to 9.3% of 
adults aged 20–79 years (International Diabetes Federation 2019). The International Diabetes Federation 
has predicted that the global increase of people living with diabetes will be even faster in the future than it 
has been in the past decades. The prevalence of diabetes is strongly affected by demographic, environmen-
tal, societal and genetic factors. 
In terms of population health, diabetes is a strong risk factor for cardiovascular diseases, especially macro-
vascular diseases, such as coronary heart disease and atherosclerotic conditions. Elevated blood glucose 
causes also microvascular complications like neuro-, nephro- and retinopathy. In addition, several other 
comorbidities including depression and several cancers have been found to be associated to diabetes. 
Due to the high and increasing prevalence of diabetes the resources needed to treat the condition and its 
complications are substantial. To tackle the related human and financial challenges, it is of outmost im-
portance to succeed in preventing diabetes and its complications. 
The aim of the Diabetes in Finland (FinDM) project is to study the incidence, prevalence, care and costs of 
diabetes as well as complications and comorbidities related to diabetes. For the purpose, a database based 
on a linkage scheme of a wide range of health care admistrative registers has been constructed in the pro-
ject. Furthermore, the aim is to extend the database to cover data related to effectivity and quality of care 
and use of resources in primary and specialised health care. The FinDM database has also been compiled in 
order to boost and strengthen register-based research on diabetes in Finland.  
The FinDM project was launched in 2003 as a collaboration of the National Research and Development 
Centre for Welfare and Health (STAKES), Social Insurance Institution (KELA) and Finnish Diabetes As-
sociation. Over the years the project has gradually developed linkage schemes and methodology for moni-
toring the diabetes situation in Finland (Niemi and Winell 2005, Sund and Koski 2009). Currently, the 
project works in collaboration with the Diabetes Quality Register of the Finnish Institute for Health and 
Welfare (THL).  
This publication describes the structure of the diabetes database compiled in the FinDM project and pre-
sents the methods used to construct the database and to define the main indicators used. The current data-
base is the third major revision of the structure of the original FinDM data compilation. In order to give an 
introduction to the research potentials of the FinDM data, the publication also shortly reviews research 
carried out using the earlier versions of the FinDM database.  
Classification of diabetes 
Diabetes is a group of diseases where the common feature is elevated blood glucose resulting from disturb-
ance in insulin production that can vary from a total lack of insulin to elevated insulin level, often com-
Background 
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bined with insulin resistance (impairment of insulin action in the target tissues). The changes in insulin 
production and effect can be of genetic, epigenetic, environmental or life-style origin. 
Diabetes is classified into different types according to the type of changes in insulin production or insulin 
effect. According to the International Classification of Diseases (ICD 10) there are five main groups of 
diabetes classified as E10-E14. The two most common are type 1 (E10) and type 2 diabetes (E11). Acute or 
chronic pancreatitis may cause secondary diabetes with insulin deficiency. Corticosteroid use can result to 
secondary diabetes with insulin resistance. There are also various forms of diabetes due to monogenic 
origin. 
In T1D, the insulin producing cells in pancreas are destroyed in an autoimmune process. This can take 
place from the infant period to the age of forty years and beyond. In T1D, insulin production in pancreas 
decreases drastically from the normal level even to non-production. This results in highly elevated blood 
glucose, and without insulin compensation, to ketoacidosis and death. Autoimmune diabetes starting later 
in life (Latent autoimmune diabetes in adults; LADA) often manifests as slowly progressing T1D. It is 
usually first considered and treated as T2D until the shortage of insulin calls for insulin treatment. 
In T2D, blood glucose is not lowered by insulin in a normal way due to insulin resistance. This results in 
elevated insulin levels. If pancreas fails to compensate for insulin resistance, blood glucose increases to 
diabetes levels. Obesity, especially excess fat in liver, and lifestyle habits such as unhealthy diet, lack of 
exercise and sedentary behavior predispose to insulin resistance and T2D. T2D is a part of the metabolic 
syndrome, which is characterized by dyslipidaemia, hypertension and abdominal obesity.  
Pregnancy and weight gain increase the need for insulin. If the pancreas is not able to compensate for the 
increased need of insulin, gestational diabetes, defined as hyperglycemia first time diagnosed during preg-
nancy, may develop. Gestational diabetes is usually treated with diet but also metformin or insulin treat-
ment is used. Women with gestational diabetes are at increased risk for developing diabetes later in life. 
In register research the different types of diabetes are often difficult to distinguish which results in using 
only three major categories, i.e. type 1, type 2 and gestational diabetes. As a result, the diabetes categories 
are not distinctly defined but, for instance, autoimmune diabetes LADA may fall in either category of type 
1 and type 2 depending on the progress of the disease process. 
Incidence and prevalence of diabetes 
The incidence and prevalence of diabetes have grown fast worlwide (International Diabetes Federation 
2019). The same development has been observed in Finland during the last decades (Niemi and Winell 
2005, Abouzeid et al 2015). Obesity and sedentary lifestyle play major roles in developing of T2D (Wu et 
al 2014). This is already reflected in the high number of T2D among young people (Mayer-Davis et al 
2017). 
An increase in the incidence of T1D has taken place as well. The increase has been especially steep in 
childhood T1D in Finland (Harjutsalo et al 2013). The changes in the incidence of adulthood T1D are not 
well known.  
In both T1D and T2D, the prevalence has increased both due to the growing incidence and longer life-
expectancy of people with diabetes. 
Background 
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Complications and comorbidities associated with diabetes 
Inadequate management of diabetes increases the risk of micro- and macrovascular complications. Re-
thinopathy, nefropathy and neuropathy are associated with elevated blood glucose levels and hypertension. 
Cardiovascular complications are common in diabetes (Beckman et al 2013). Diabetes is also a strong risk 
factor for chronic kidney disease and renal failure (Skupien et al 2019, Thomas et al 2016). 
Several other comordities with a less direct link have been associated with diabetes. These conditions found 
to be more common among people with diabetes include depression (Roy and Lloyd 2012), dementia 
(Ninomiya 2019), and mortality due to accidents, suicide and alcohol (Niskanen et al 2018). 
Economic burden of diabetes 
T1D and T2D are associated to increased health care costs (Seuring et al 2015, Ng et al 2014). Due to the 
high prevalence, diabetes brings considerable economic burden on societies worldwide, and this burden is 
expected to grow. 
High costs accrued from diabetes and its treatment have also been observed in Finland. An increase of 35% 
in the total health care costs among persons with diabetes has taken place between 2002 and 2011. In the 
year 2011, estimated health care costs of persons with diabetes were 8.8% of the total health care expendi-
ture in Finland (Koski et al 2018). 
Diabetes complications have a substantial impact on the health care costs (Williams et al 2002, American 
Diabetes Association 2018, Brommer et al 2018). In Finland in 2011, health care costs of persons with 
diabetic complications were on average 2.2-fold compared to persons with diabetes but without complica-
tions (Koski et al 2018).  
The impact of diabetes has been demonstrated on work ability and diabetes may be a cause to sick leave, 
early disability retirement, and lower productivity at work. When assessing the costs of diabetes to the 
whole society, these productivity costs may contribute heavily. In 2007 the costs of lost productivity were 
estimated to equal the health care costs caused by diabetes in Finland (Jarvala et al. 2010). 
Purpose and objectives of the research 
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Purpose and objectives of the research 
The aim of the FinDM research project is to study the incidence, prevalence, care and costs of diabetes as 
well as complications and comorbidities related to diabetes. 
In addition, as a challenge of the current phase of the project the aim is to develop the database to improve 
the coverage of data related to efficiency and safety of care and use of resources in primary and specialised 
health care. The FinDM project includes research on regional differences of the incidence of diabetes and 
its complications, as well as regional differences in costs and care. Further, the research aims to find asso-
ciations of diabetes care with rare conditions in patients with diabetes. 
The FinDM project co-operates actively with the Finnish Quality Register (FQR) pilot for diabetes. The 
FQR pilots are coordinated by the Finnish Institute for Health and Welfare (THL). The project aims to 
develop permanent quality register for the care of eight diseases and conditions in health care in Finland 
(Jonsson et al 2019). 
The FinDM database may be used for research purposes on certain conditions. The FinDM research project 
has been granted permission by the competent register authorities to use the FinDM data along the lines 
defined in the FinDM research project plan. According to the agreed procedure, each new research proposal 
has to be approved by the FinDM advisory board making decisions on the use of the FinDM data. As far as 
possible, the contact persons and members of the advisory board of the FinDM project offer their advice 
and co-operate with external researchers. In the case of a new external research project, the FinDM project 
has to apply for the extension for the research permission from the register authorities in order to disclose 
new research topics or new users for the FinDM data. 
Data and definitions 
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Data and definitions 
The FinDM database has been compiled using register-based data from several national administrative and 
health care registries. The database comprises register data from the Finnish Institute for Health and Wel-
fare (THL), the Social Insurance Institution of Finland (KELA), Statistics Finland, the Finnish Centre for 
Pensions (ETK) and the Finnish Kidney and Liver Association.  
The permissions to use the register data were obtained through applications to respective register holders: 
 THL (THL/1047/6.02.00)
 KELA (74/522/2018)
 Statistics Finland (TK-53-922-18)
 ETK (ETK/SUTI 18012)
 Finnish Kidney and Liver Association (excerpt of proceedings, 1
st
 December 2014 (§4b))
 Statistics Finland for sociodemographic and census data (TK-53-531-16)
Researchers approved to use the FinDM database have to sign confidentiality obligations for the respective 
register holders. The ethical approval for the study was received from the Research Ethics Committee of 
THL (excerpt of proceedings 5/2018 (§791)). 
Identification of people with diabetes 
The FinDM project aims to identify all persons who have been diagnosed for diabetes in Finland by collect-
ing any potential entries concerning diabetes in registers.  
Individuals were deemed potentially having diabetes if they met at least one of the following criteria: 
 Diabetes diagnosis in the Hospital Discharge Register (ICD-8, 1969-1986)
 Diabetes diagnosis in the Hospital Discharge Register (ICD-9, 1987-1993)
 Diabetes diagnosis in the Care Register for Health Care (ICD-9, 1994-1995)
 Diabetes diagnosis in the Care Register for Health Care (ICD-10, 1996-2017)
 Diabetes diagnosis in the Register of Primary Health Care Visits (ICD-10 and ICPC-2, 2011-
2017)
 Diabetes diagnosis or entry (checkbox for diabetes, insulin initiation and pathological result in glu-
cose tolerance test) in the Medical Birth Register (mother and child, ICD-9 and ICD-10, 1987-
2017)
 Diabetes diagnosis in the Causes of Death Statistics (ICD-8, ICD-9 and ICD-10, 1971-2017)
 Entitlement to elevated reimbursement for antidiabetic medications (codes 103, 171, 215, 285,
371) in the Special Reimbursement Register (1964-2017)
 Entries of purchase of antidiabetic medications (ATC codes A10*) in the Prescription database
(1993-2017)
Diagnosis codes used in the identification of persons with diabetes are presented in Table 1. 
The personal identity codes (Digital and Population Data Services Agency 2020) of potential persons with 
diabetes from registers maintained by THL and Statistics Finland were forwarded to KELA and completed 
with the personal identity codes of potential persons with diabetes in the KELA registers. In KELA, the 
cohort was scrutinized to manage individuals with altered personal identity codes. In addition, the cohort 
was attached with data on municipality of residence on December 31
st
  in each year in 1986-2017. After
that the personal identity codes were replaced with research numbers by THL. The register authority within 
THL, in the capacity of the register holder, maintains the key to personal identity codes and research num-
Data and definitions 
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bers for update and linkage purposes. The FinDM database is accessed by the researchers using the pseu-
donymised research numbers.  
Table 1. Diagnosis codes used in the identification of persons with diabetes. 
ICD-8 ICD-9 ICD-10 ICPC-2 
Type 1 diabetes 250?B E10, O24.0 T89 
Type 2 diabetes 250?A E11, O24.1 T90 
Other type of dia-
betes 
250?C E12, E13, O24.2, 
P70.2 
Gestational diabe-
tes 
7611 6480, 7750 O24.4, O24.9, 
P70.0, P70.1 
W85 
Unspecified 250 250?X, 3620 E14, G59.0, G63.2, 
H28.0, H36.0, I79.2, 
M14.2, M14.6, 
N08.3, O24.3 
The final cohort comprises 1,151,199 distinct individuals with potential diabetes. 
Follow-up data 
Figure 1 describes the collection of follow-up data for the cohort of potential persons with diabetes.  
Data including visits to specialised health care were obtained from the Hospital Discharge Register and the 
Care Register for Health Care (Finnish Institute for Health and Welfare 2020a) between 1969 and 2017, 
including ambulatory visits to specialised health care in 1998-2017. Data of visits to the public primary 
care were obtained from the Register of Primary Health Care Visits (Finnish Institute for Health and Wel-
fare 2020c) in 2011-2017. Data on care periods in social care institutions were collected from the Care 
Register of Social Welfare (Finnish Institute for Health and Welfare 2020d) between 1994 and 2017. The 
compiled data on care include variables concerning, among others, service provider, specialty, date of arri-
val and discharge, discharge destination, main and subsidiary diagnoses as well as main and subsidiary 
procedures.  
Data on all deliveries were obtained from the Medical Birth Register (Finnish Institute for Health and Wel-
fare 2020b) in 1987-2017. All cases of cancer were obtained from the Finnish Cancer Registry between 
1953 and 2017 (Pukkala et al 2018). Data on visual impairment were provided by the Finnish Register of 
Visual Impairment (Finnish Federation of the Visually Impaired 2020) for 1983-2017. Data on treatment 
and diagnoses of patients with nephropathy were obtained from the Finnish Registry for Kidney Diseases 
(Finnish Kidney and Liver Association 2020) in 1965-2013.  
The dates and causes of death were obtained from the Causes of Death Statistics (Statistics Finland 2020b) 
in 1971-2017. Data include information on causes determined by a doctor, diagnoses pertaining to the pri-
mary cause of death, indirect cause of and contributory causes of death. 
Sociodemographic and census data were linked to the data in the remote access environment Fiona of Sta-
tistics Finland. Several FOLK modules (Statistics Finland 2020b) starting from the population census of 
1970 are available for use in Fiona including data on income, education, employment, pensions and house-
holds.  
Data and definitions 
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The Register of Special Reimbursement of medicines (Social Insurance Institution 2020b) was used to 
obtain entitlements to special reimbursement between 1964 and 2017. The register contains entitlements to 
reimbursement of medicine expenses at the special rate, to limited reimbursement, or to reimbursement for 
clinical nutrients, which are approved when certain criteria are met. The data includes dates, codes and 
diagnoses for the special reimbursements. Data on reimbursable purchases of medications between 1994 
and 2017 were provided by the Prescription database (Social Insurance Institution 2020a) including ATC 
code, date of purchase, costs, defined daily dose (DDD) and information on package identification numbers. 
In addition, data on pensions (including national and disability pensions) and imbursements for private 
services as well as on sickness, care and rehabilitation allowances (Social Insurance Institution 2020c) were 
obtained from KELA. Data on disability pensions also included diagnoses on which the disability pensions 
were based. 
Data on approved and rejected earnings-related and national pensions were collected from the Pension 
Register (Finnish Centre for Pensions 2020) of the Finnish Centre for Pensions. Information included the 
type and duration of pension together with monthly payments and accruals covering years 1998-2017. To-
gether, pension data from KELA and ETK contain information of all pensions in Finland.  
Finally, from the Earnings and Accrual Register of the Finnish Centre for Pensions, data on employment 
and periods of entrepreneurship as well as periods when person did not receive income as paid salary were 
collected for years 1998-2017. Data include annual income and benefits from these periods. 
Further, permissions to use the register data obtained from the respective register holders allow us to link 
data on visits to primary health care providers and data obtained from the Prescription Centre and Patient 
Data Repository of the Kanta services (Kanta Services 2020) to the data.  
Data and definitions 
THL Discussion Paper 19/2020 11 FinDM database on diabetes in Finland 
Figure 1. Collection of follow-up data for the diabetes cohort. 
Sources of follow-up data 
Social Insurance Institution  
Register of Special Reimbursement (1964-2017) 
Pension database (1970-2011) 
Prescription database (1994-2017) 
Demographics 
Reimbursed medi-
cation 
purchases 
Health service 
use 
Comorbidities 
Sickness 
allowances 
Pensions 
Earnings 
Hospital Discharge Register (1969-1993) Care Register for Health Care (1994-2017) 
Care Register of Social Welfare (1994-2017) Register of Primary Health Care (2011-2017) 
Finnish Institute for Health and Welfare 
Causes of Death Statistics (1971-2017) Socioeconomic and census data (1970-2017) 
Statistics Finland 
Earnings and Accrual Register (1998-2017) Pension Register (1998 -2017) 
Medical Birth Register (1987-2017) Finnish Cancer Registry (1953-2017) 
Register of Visual Impairment (1983-2017) Registry for Kidney Diseases (1965-2013) 
1965-2017
Complementing registers 
Sickness allowances etc. (1982-2017) 
Data and definitions 
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Inclusion and exclusion criteria for people with diabetes 
The cohort of potential people with diabetes was processed to create a research database which includes 
individuals who are, with sufficient accuracy, identified as persons having diabetes. 
Individuals are included in the research if they have a diabetes diagnosis in the Hospital Discharge Register, 
the Care Register for Health Care, the Register of Primary Health Care Visits, or the Cause of Death statis-
tics. Further, an entitlement to special reimbursement for antidiabetic medications in the Special Reim-
bursement Register or a purchase of antidiabetic medications in the Prescription database count for inclu-
sion in the research data. The date of the first entry of diabetes in the registers was defined as the date of the 
onset of diabetes. 
A major separation criterion in the database concerns gestational diabetes. Diagnosis codes for gestational 
diabetes were searched for in the Hospital Discharge Register, the Care Register for Health Care, the Regis-
ter of Primary Health Care Visits, and the Cause of Death statistics. Besides, any entry for gestational dia-
betes in the Medical Birth Register was deemed as a criterion of gestational diabetes. If no other entries for 
diabetes except gestational diabetes were found, these persons were defined as persons with gestational 
diabetes. In addition, the Hospital Discharge Register was searched for diagnoses of pregnancy (ICD-8: 
650-662) preceeding the year of 1987. These dates were modified to cover the time for pregnancy (9 
months) and postpartum period (2 months) and compared to the individual’s other dates of diabetes entries. 
If all entries of diabetes diagnosis for the individual occurred during the time of pregnancy and postpartum 
period, they were defined as persons with gestational diabetes. Respectively, deliveries from the Medical 
Birth Register since 1987 were compared to purchases of antidiabetic medications in the Prescription data-
base. If no other entries of diabetes diagnosis for the individual was found and the purchases of antidiabetic 
medications only occurred during the time of pregnancy and postpartum period, those individuals were 
defined as being diagnosed with gestational diabetes. The identification of persons with gestational diabetes 
in the FinDM database enables research also on gestational diabetes.  
Another separation criterion of research data is polycystic ovary syndrome (PCOS). Metformin is also used 
as medication among women with PCOS. In accordance with the definition of the National Diabetes Regis-
ter of Denmark (Carstensen et al 2011), women with purchases of metformin (ATC code: A10BA02) in the 
age between 20 and 39 years as an only indication on diabetes were excluded from the diabetes cohort. In 
addition, the Hospital Discharge Register, the Care Register for Health Care and the Register of Primary 
Health Care Visits were searched for diagnoses of PCOS (ICD-9: 2564, and ICD-10: E282), which can be 
used in later analyses concerning links between PCOS and diabetes. 
Finally, the individuals with only one purchase of metformin (ATC code: A10BA02) in the registers were 
considered to have insufficient evidence on diabetes and they were excluded from the research data.  
After the introduction of inclusion and exclusion criteria to the database, 887,210 persons were included in 
the diabetes cohort. 
Classification of people with diabetes 
Due to several reasons the definite classification of people with diabetes into the T1D and T2D categories 
was challenging as in many other register studies. First, the classification and recording practices of diseas-
es, such as ICD-8, ICD-9, ICD-10 and ICPC-2, has changed during the study period of 1964-2017. Second, 
the time span of the different register sources varies considerably during the study period. Third, the care 
practices including the use of medication varied during the study period. Fourth, the follow-up time from 
the onset of diabetes until death or the end of 2017 varied greatly from null to decades.  
Data and definitions 
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Due to the complicity of classification in diabetes types, we decided to classify persons with diabetes based 
on the information of the first year following the onset of diabetes to achieve an equal potential time for 
consideration. The following hierarchy was created on which the definition was based (using diagnosis 
codes presented in Table 1). 
1. A diagnosis code for the special reimbursement for antidiabetic medication in the Special Reim-
bursement Register
2. A diagnosis code for diabetes in hospital discharges of the Hospital Discharge Register or the Care
Register for Health Care
a. Diagnosis made in specialised care
b. Main diagnosis being more precise than subsidiary diagnosis
c. Latter date of diagnosis being more precise than former date
3. A diagnosis code for diabetes in the ambulatory visits to specialised health care in the Care Regis-
ter for Health Care
a. Diagnosis made in specialised care
b. Main diagnosis being more precise than subsidiary diagnosis
c. Latter date of diagnosis being more precise than former date
4. A diagnosis code for diabetes in the Register of Primary Health Care Visits
a. Main diagnosis being more precise than subsidiary diagnosis
b. Latter date of diagnosis being more precise than former date
5. Purchases of antidiabetic medications in the Prescription database
a. Only purchases of insulin (ATC code: A10A) => T1D
b. Only purchases of insulin (ATC code: A10A) and metformin (ATC code: A10BA02)
and age of under 40 years => T1D
c. Other => T2D
6. A diagnosis code for diabetes in the Cause of Death Statistics
a. Primary causes of death being more important than contributory causes of death
7. Age at the onset of diabetes
a. Age of under 40 years => T1D
b. Age of 40 years or more => T2D
Definition of the follow-up indicators of diabetes 
Indicators used in the follow-up were formed in order to identify complications and outcomes of diabetes. 
Chosen indicators are based on the earlier research conducted in the project. To coordinate the methodolog-
ical approaches, the FinDM defintions were compared with the definitions developed in the FQR pilot on 
diabetes to finalise the list of the indicators.  
Diagnosis and procedure codes used to define major complications and outcomes of diabetes in the FinDM 
project are presented in Table 2. 
Some of the other follow-up indicators of interest include gastric bypass, liver disease (NAFLD, liver cir-
rhosis, liver cancer), mouth infection, severe depression, psychotic disorders, dementia, thyroid disorders, 
coeliac disease and osteoporosis.  
Data and definitions 
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Table 2. Diagnosis and procedure codes used to define major complications and outcomes of diabetes. 
Category ICD-10 Procedure codes 
1. Cardiovascular complica-
tions
includes subcategories 1.1.-1.4. 
1.1. Ischemic heart disease I20-I25 FNA-FNE, FN1AT, FN1BT, 
FN1ST, FN1YT, FN2, FN3CT, 
TFN40, TFN50 (and relevant 
supplementary codes for 
patients with advanced 
cardiac condition) 
1.2. Acute myocardial infarction 
(AMI) 
I21, I46, R96, R98 
1.3. Heart failure I50 
1.4. Atrial fibrillation and flutter I48 
2. Cerebrovascular complica-
tions in diabetes
I63.0-I63.5, I63.7-I66.9, 
I67.2, I69.3, G45 
PA 
2.1. Ischemic stroke I63.0-I63.5, I63.7-I64.9, G45 
3. Foot complications in diabe-
tes
includes subcategories 3.1.-3.4. 
3.1. Peripheral artery disease 
(PAD) 
I70.2, I79.2, E10.5, E11.5, 
E12.5, E13.5, E14.5 
PD-PG 
3.2. Non-traumatic amputation includes subcategories 3.2.1.-3.2.2.  
3.2.1. Major amputation NFQ10, NFQ20, NGQ10, 
NGQ20, NHQ10, NHQ20 
3.2.2. Minor amputation NHQ30, NHQ40 
3.3. Diabetic foot ulcer L03.1, L97, S91, T93, 
M86.1-M86.4, M86.6-M86.9 
NHK99, NHS20, NHS99, 
NHW, QDB05, QDG20, 
QDG30, QDG99 
3.4. Charcot foot M146 
4. Diabetic nephropathy E10.2, E11.2, E12.2, E13.2, 
E14.2, N08.3, N18, Z49, Z94 
KAS, TK800, TK820 
4.1. Chronic kidney disease N18 
4.2. Dialysis Z49 TK800, TK820 
4.3. Transplantation of kidney KAS 
4.4. Transplanted kidney status Z94 
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Table 2. (continued). 
5. Eye complications in diabe-
tes
E10.3, E11.3, E12.3, E13.3, 
E14.3, H28.0, H34, H36.0, 
H40.5, H42.0, H43.1, H45.0, 
H54 
CKC12/CKD05/CKD60/CKD65
+E10-E14
5.1. Diabetic retinopathy H36.0, 
H43.1+E10.6/E11.6/E12.6/ 
E13.6/E14.6, 
H45.0+E10.6/E11.6/E12.6/ 
E13.6/E14.6 
CKC12/CKD05/CKD60/CKD65
+E10-E14
5.2. Blindness and impaired 
vision  
H54 
6. Diabetic neuropathy E10.4, E11.4, E12.4, E13.4, 
E14.4, G57.1, G57.3, G57.5, 
G59.0, G63.2, G73.0, G99.0, 
H49, I95.1, N48.4 
7. Death (causes as underlying 
cause of death) 
Any cause  
7.1. Cardiovascular death I21, I46+R96/R98, I63, I64, 
G45 
7.2. Cancer death C00-D48 
7.3. Accidental death V01-X59 
7.4. Suicide X60-X84 
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Description of primary data 
Numbers of persons with diabetes 
The incident number of persons with T1D in the FinDM database has remained relatively stable after the 
first years of the database of 1964 and 1965. The number of newly diagnosed persons with T1D peaked in 
2008 with 2,144 new cases. In 2017, 1,504 new persons with T1D were identified. Likewise, 2008 was the 
year with the highest number (36,252) of incident T2D. In the last year of follow-up, 2017, the incident 
number of T2D was 22,961 (Figure 2).  
The development in the registers, which make the data source for the FinDM database, are reflected in the 
incident numbers of both T1D and T2D. T1D was identified from the year 1964, when the Special Reim-
bursement Register started. From the early 1970s, the emergence of recording of diagnoses in the Hospital 
Discharge Register produced a surge in incident persons with T2D. This trend was extended with initiation 
of Prescription database in the early 1990s. Changes in medications and other treatment practices of diabe-
tes, reimbursement practices and programmes to improve diagnosing of T2D patients have also affected the 
incident numbers of persons with T2D.  
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Figure 2. Incident number of persons with type 1 diabetes (T1D) and type 2 diabetes (T2D) in 1964-2017 
in Finland. 
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Figure 3. Prevalent number of persons with type 1 diabetes (T1D) and type 2 diabetes (T2D) on the last 
day of each year in 1964-2017 in Finland. 
The number of persons living with T1D has grown steadily throughout the study period being 53,780 in the 
end of 2017. The prevalence number of T2D has been more dependent on changes in the register sources 
used, especially during the first decades of the study. Anyhow, the prevalence number of T2D has grown 
rapidly, especially in 2000s, reaching 401,911 persons by the end of year 2017 (Figure 3). 
Incidence and prevalence of persons with diabetes 
The age-standardised incidence rate of T1D per 10,000 person years in the general population has varied 
somewhat in the 2000s. As for T2D, there was an additional increase in the incidence rate around 2008-
2011, probably linked to the diabetes prevention and treatment project DEHKO (Diabeteksen ehkäisyn ja 
hoidon kehittämisohjelma 2011, Dehkon 2D -hanke 2009) Since then, however, the increase has levelled 
off (Figure 4). 
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Figure 4. Age-standardised incidence rate per 10,000 person years for type 1 diabetes (T1D) and type 2 
diabetes (T2D) in 2000-2017 in Finland. 
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Figure 5. Age-standardised prevalence rate per 10,000 person years for type 1 diabetes (T1D) and type 
2 diabetes (T2D) in the last day of each year in 2000-2017 in Finland. 
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Between 2000 and 2017, the age-standardised prevalence rate of T1D has steadily increased from 68 to 96 
per 10,000 in the general population. During the same period for T2D it increased from 391 to 725 per 
10,000 person years (Figure 5).  
Figure 6. Age-standardised incidence rate per 10,000 person years in 2017 of type 1 diabetes (T1D) and 
type 2 diabetes (T2D) in the hospital districts and Åland Islands in Finland. 
Figure 6 shows the age-standardised incidence rates in the hospital districts and Åland Islands in 2017. The 
Åland Islands had the highest incidence of T1D and the lowest incidence of T2D but the rates may be unre-
liable due to the small population. An east-west difference is seen in the incidence of T2D. 
Figure 7. Age-standardised prevalence rate per 10,000 person years in 2017 of type 1 diabetes (T1D) 
and type 2 diabetes (T2D) in the hospital districts and Åland Islands in Finland. 
The age-standardised prevalence rates in the hospital districts in 2017 show lower prevalence of T1D in the 
coastal and northernmost districts (Figure 7). As for T2D, the coastal and southern districts have lower 
prevalence rates compared to the northern ones. 
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The age-standardised incidence and prevalence rates were calculated with direct standardisation method 
using the total Finnish population in 2017 as the standard population.  
Previous use of the FinDM data in research 
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Previous use of the FinDM data in research 
The FinDM database has been used for wide scope of research on diabetes, and its care, complications and 
outcomes, as well as costs of diabetes care. In the chapter, the themes of research based on the FinDM data 
are shortly presented. The numbered references refer to the list of FinDM publications (Appendix 1). 
A major objective of launching the FinDM project was to produce comprehensive data on morbidity related 
to diabetes. Accordingly, the FinDM data have primarily been used for research aiming at epidemiological 
and public health monitoring of diabetes in Finland, including trends in the incidence and prevalence of 
diabetes [15, 41, 46-49]. In association to these aims, several publications have been produced on methodo-
logical approaches of conducting register-based research on diabetes and of the challenges concerning 
composing a register on diabetes based on a range of nationwide administrative registers [14, 38, 48, 49, 63, 
66]. 
Complications and comorbidities of diabetes have been a subject of several of studies in the FinDM re-
search project. Several publications have addressed a wider range of complications and attempted to dis-
play an overall picture of challenges and occurance of main complications [24, 25, 41, 45, 53]. Prevention, 
incidence, and treatment and outcomes of cardiovascular and cerebrovascular diseases have been studied in 
several articles [2-5, 9-11, 18, 21, 32, 39, 40, 43, 58, 59, 62]. Studies on amputations [1, 7, 13, 17] and 
renal disease [20, 29, 35, 61, 66] among people with diabetes have also been published. Some studies have 
concerned the incidence of depression [8, 19] and fractures [44] among people with diabetes. 
The FinDM database has been also used for linkages to health care registers which are not included in the 
orginal FinDM linkage scheme. Data obtained from the linkage of the FinDM register and the Finnish Can-
cer Registry have been used for several studies addressing the incidence and prognosis of cancer among 
people with diabetes [16, 22, 23, 26, 28, 30, 31, 33, 34, 36, 52, 54, 56, 67, 68]. Another major topic based 
on these data is the associations of pharmaceuticals and cancer incidence among persons with diabetes. 
This topic has been studied addressing medications used in the care of diabetes [22, 26, 28, 30, 31, 33, 36, 
56, 67, 68] and medications used for other purposes [8, 9, 18-22, 39, 59, 62]. 
The fourth major area of research is mortality among people with diabetes, which has been a frequent topic 
in the research [6, 12, 16, 28, 31, 33, 37, 61, 67, 68]. Mortality among the diabetes population has also been 
examined in terms socioeconomic [5, 6, 10, 12, 13, 63] or regional variation [24, 32, 40, 65]. 
A developing field in the use of the FinDM data is researching the costs accrued to diabetes and its care [42, 
45, 50, 55, 57, 60]. Excess costs related medication and service use among people with diabetes have been 
estimated on a national level. Diabetes and its complications have an effect also on work ability and the 
participation in the working life [27, 64]. Costs arising from lost productivity due to exit from the labor 
force (sick leaves, early retirements and premature deaths) have also been estimated. 
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Concluding remarks 
In general, the FinDM database provides high quality data for monitoring and researching diabetes and its 
care. The database is comprehensive and covers all persons with diabetes diagnosis in some of the several 
health care and health insurance registers in Finland. In addition, the FinDM database is a nationwide co-
hort with a long study period from 1964 to 2017 and wide scope of follow-up data from several register 
sources. Since 2010, the coverage of persons with diabetes is considered to be good in the FinDM database. 
However, there are some limitations in the FinDM data. While some persons with type 2 diabetes are treat-
ed with lifestyle modification but without any medications, they may have no diagnostic entries on diabetes 
in any ambulatory care registers and thus they are not included in the FinDM data. An obvious limitation of 
the FinDM database for research purposes is the lack and poor coverage of indicators describing  primary 
health care and diagnostic data, including visits to occupational health care and private health care produc-
ers. Another challenge has been the long intervals in opportunity for updating the cohort to ensure up-to-
date data on persons with diabetes. 
In the future, the FinDM project aims to continue research on the incidence, prevalence, care and costs of 
diabetes as well as its complications and comorbidities. The planned new research topics for the future 
include research on comorbidities and complications not studied earlier as well as participation of persons 
with diabetes in working life. Among new specific research topics, the project aims to extend the use of the 
FinlDM data to study gestational diabetes and polycystic ovary syndrome and their associations with diabe-
tes. The project is also looking possibilities to link more accurate clincal and diagnostic data from primary 
and specialised health care to the FinDM database in order to develop the indicators of content and quality 
of care. The project is supporting to the Finnish Quality Register Pilots in order to facilitate the launch of a 
national quality register on diabetes. The project is also continuing collaboration with external researchers 
from other research institutes and universities. As mentioned above the FinDM database is open for re-
search use by external researchers use on the predefined terms as described earlier. 
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